Holen Sie sich die Stockscreener-App
5.25
1.32%
-0.07
Handel nachbörslich:
5.25
Schlusskurs vom Vortag:
$5.32
Offen:
$5.3
24-Stunden-Volumen:
228.07K
Relative Volume:
1.33
Marktkapitalisierung:
$199.69M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
1.7736
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
-0.94%
1M Leistung:
-22.79%
6M Leistung:
-60.94%
1J Leistung:
-66.81%
1-Tages-Spanne:
$5.09
$5.36
1-Wochen-Bereich:
$4.93
$5.47
52-Wochen-Spanne:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.25 | 196.27M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada Therapeutics Inc. Added to High Probability Setup ListJuly 2025 Final Week & Safe Capital Investment Plans - thegnnews.com
Historical volatility pattern of Entrada Therapeutics Inc. visualizedJuly 2025 PreEarnings & Stock Portfolio Risk Control - Newser
Entrada Therapeutics Inc. recovery potential after sell offJuly 2025 Final Week & Community Consensus Stock Picks - Newser
Will a bounce in Entrada Therapeutics Inc. offer an exitEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Entrada Therapeutics Inc. still worth holding after the dipIPO Watch & Community Driven Trade Alerts - Newser
Real time breakdown of Entrada Therapeutics Inc. stock performanceWeekly Trading Summary & Stock Portfolio Risk Management - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.IPO Watch & Weekly Chart Analysis and Trade Guides - Newser
Can Entrada Therapeutics Inc. disrupt its industryQuarterly Performance Summary & Long Hold Capital Preservation Plans - mustnews.co.kr
What moving averages say about Entrada Therapeutics Inc.2025 Earnings Impact & Technical Entry and Exit Tips - Newser
Tools to assess Entrada Therapeutics Inc.’s risk profilePortfolio Gains Summary & Accurate Trade Setup Notifications - Newser
Is Entrada Therapeutics Inc. stock reversal real or fakeJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - Newser
How Entrada Therapeutics Inc. stock performs during market volatilityFree Accurate Buy Point for Momentum Stocks - Newser
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaSmart Stock Forecast Using AI Algorithms - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyTrading Opportunities Forecast by AI Insight - Newser
Measuring Entrada Therapeutics Inc.’s beta against major indicesBuy and Hold Position Summary Review - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - 富途牛牛
HC Wainwright Issues Pessimistic Outlook for TRDA Earnings - Defense World
Roth Capital Issues Pessimistic Forecast for TRDA Earnings - Defense World
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
William Blair Issues Negative Forecast for TRDA Earnings - Defense World
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):